These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19383573)

  • 41. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
    Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
    Haffner SM
    Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol.
    Gómez-Marcos MA; Recio-Rodríguez JI; Rodríguez-Sánchez E; Castaño-Sánchez Y; de Cabo-Laso A; Sánchez-Salgado B; Rodríguez-Martín C; Castaño-Sánchez C; Gómez-Sánchez L; García-Ortiz L
    BMC Public Health; 2010 Mar; 10():143. PubMed ID: 20298558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The metabolic syndrome and type 2 diabetes.
    Poole R; Byrne CD
    Minerva Endocrinol; 2005 Sep; 30(3):139-59. PubMed ID: 16208305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians - the Chennai Urban Rural Epidemiology Study (CURES-38).
    Mohan V; Sandeep S; Deepa M; Gokulakrishnan K; Datta M; Deepa R
    Diabetes Obes Metab; 2007 May; 9(3):337-43. PubMed ID: 17391160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of metabolic syndrome in Pakistan.
    Basit A; Shera AS
    Metab Syndr Relat Disord; 2008 Sep; 6(3):171-5. PubMed ID: 18699720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New insights into understanding cardiometabolic risk. Introduction.
    Fonarow GC; Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S1-2. PubMed ID: 17934389
    [No Abstract]   [Full Text] [Related]  

  • 49. The cardiometabolic syndrome in the adolescent.
    Gardner M; Gardner DW; Sowers JR
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():964-8. PubMed ID: 18806711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does fitness improve the cardiovascular risk profile in obese subjects?
    Halland H; Lønnebakken MT; Saeed S; Midtbø H; Cramariuc D; Gerdts E
    Nutr Metab Cardiovasc Dis; 2017 Jun; 27(6):518-524. PubMed ID: 28528703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome.
    Gateva AT; Kamenov ZA
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):161-6. PubMed ID: 22727921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic syndrome and cardiovascular disease.
    Qiao Q; Gao W; Zhang L; Nyamdorj R; Tuomilehto J
    Ann Clin Biochem; 2007 May; 44(Pt 3):232-63. PubMed ID: 17456293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance.
    Kendall DM; Harmel AP
    Am J Manag Care; 2002 Dec; 8(20 Suppl):S635-53; quiz S654-7. PubMed ID: 12510788
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2).
    Cheung BM; Wat NM; Man YB; Tam S; Cheng CH; Leung GM; Woo J; Janus ED; Lau CP; Lam TH; Lam KS
    Am J Hypertens; 2008 Jan; 21(1):17-22. PubMed ID: 18091739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ; Sposito AC
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abdominal obesity and metabolic syndrome.
    Després JP; Lemieux I
    Nature; 2006 Dec; 444(7121):881-7. PubMed ID: 17167477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Prevalence and characteristics of type 2 diabetics in a Spanish city. DIABETCIEZA 2010].
    Caballero Corredor J
    Semergen; 2012; 38(1):9-15. PubMed ID: 24847534
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage.
    Mulé G; Cottone S; Nardi E; Andronico G; Cerasola G
    Minerva Cardioangiol; 2006 Apr; 54(2):173-94. PubMed ID: 16778751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Background and treatment of metabolic syndrome: a therapeutic challenge.
    van Zwieten PA; Mancia G
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):206-14. PubMed ID: 16959752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.